adhesion G protein-coupled receptor G4Genealiases: GPR112 · PGR17 · RP1-299I16
Q-omics provides the consensus-scored ADGRG4 profile across patient tissues and cancer cell-line models. ADGRG4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, ADGRG4 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, ADGRG4 RNA expression shows 7,516 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight OV, BLCA, and LUAD as cancer lineages where ADGRG4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADGRG4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADGRG4 survival associations across molecular data types. ADGRG4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADGRG4 RNA expression–survival associations across cancer types. High ADGRG4 expression shows unfavorable associations in OV, READ and LGG, but favorable associations in PAAD, SKCM and MESO. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for ADGRG4 RNA expression.
This table summarizes ADGRG4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for ADGRG4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADGRG4 shows lower tumor expression in BLCA, COAD, LUSC, LUAD, UCEC and BRCA. The BLCA box plot shows higher ADGRG4 RNA expression in normal versus tumor tissue (log2 FC = −0.220, t-test p < 0.001).
This table shows molecular features associated with ADGRG4 in patient tissues and cancer cell lines. In patient samples, ADGRG4 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ADGRG4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
